Chimeric IL-2 Targeting for Localized T Cell Expansion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neuroinflammatory diseases face challenges due to the blood-brain barrier, which prevents effective delivery of immunosuppressive agents, and systemic delivery often leads to widespread immunosuppression, making it untenable for patients.
Innovation Solution
A method involving the administration of IL-2 combined with a targeting moiety specific for the central and/or peripheral nervous system to expand regulatory T cells locally within these tissues, using a transgene with a tissue-specific promoter like GFAP to ensure localized expression and avoid systemic effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immunosuppressive agents are administered systemically to treat neuroinflammation, then the anti-inflammatory effect is improved, but widespread peripheral immunosuppression occurs making the treatment untenable
Solution Approach 1:
The patent segments the treatment approach by using a chimeric protein that separates the targeting function (brain-specific peptide) from the therapeutic function (IL-2). This allows selective delivery of immunosuppressive effects to the brain while avoiding peripheral immunosuppression, resolving the contradiction between achieving reliable anti-inflammatory effect and avoiding harmful peripheral side effects
Solution Approach 2:
The chimeric protein acts as an intermediary that mediates the delivery of IL-2 specifically to the brain. The brain-specific peptide portion targets the protein to cross the blood-brain barrier, while the IL-2 portion provides the immunosuppressive effect only within the brain, thus achieving reliable treatment without harmful peripheral immunosuppression
2Reliability
If high doses of immunosuppressive agents are used to overcome the blood-brain barrier, then the anti-inflammatory effect in the brain is improved, but wide-spread peripheral immunosuppression occurs
Solution Approach 1:
The patent applies local quality by creating a treatment that is specifically active in the brain through the blood-brain barrier crossing capability of the chimeric protein. The immunosuppressive effect is localized to the brain tissue where it is needed, while peripheral tissues remain unaffected, thus achieving reliable brain treatment without harmful peripheral immunosuppression even at effective doses
3Quantity of substance
If IL-2 is administered systemically to expand regulatory T cells, then regulatory T cell expansion is improved, but the treatment cannot be sustained due to systemic side effects
Solution Approach 1:
The chimeric protein serves as an intermediary delivery system that transports IL-2 across the blood-brain barrier to expand regulatory T cells specifically in the brain. This targeted approach achieves the desired quantity of regulatory T cell expansion in the CNS without the harmful systemic side effects that would prevent sustained treatment
Solution Approach 2:
The segmented structure of the chimeric protein (brain-specific peptide + IL-2) enables selective expansion of regulatory T cells in the brain by directing IL-2 activity to the CNS compartment only, allowing sustained treatment to achieve adequate regulatory T cell quantities without systemic toxicity
Data Source
AI summary
The invention relates to a method of expanding a population of regulatory T cells in a tissue or organ of a subject, wherein said method comprises administration of IL-2 and a targeting moiety specific for said tissue or organ, and wherein said tissue or organ is the central and/or peripheral nervous system. The invention further relates to populations of regulatory T cells produced according to the method and the production of said population in vivo. Also provided is a pharmaceutical composition comprising IL-2 and a targeting moiety as defined herein as well as a method of treating a disease or disorder mediated by inflammation or for the reduction of inflammation which comprises the methods defined herein or administration of a pharmaceutical composition as defined herein.